Changing therapeutic landscape - The last decade

Aurer, Igor (2011) Changing therapeutic landscape - The last decade. Transfusion and Apheresis Science, 44 (2). pp. 155-9. ISSN 1473-0502

Download (246kB) | Preview


Undoubtedly the most important event in the previous decade in lymphoma treatment was the establishment of immunotherapy as a prime modality. Addition of rituximab improves survival in almost every group of patients with CD20+ tumors. This has led to the appearance of a number of "me too" monoclonal antibodies (MoAbs) as well as MoAbs directed against other antigens whose usefulness remains to be proven during the next decade. We have also seen the raise and, probably unwarranted, fall of radioimmunotherapy. Conventional radiotherapy is losing ground. Regarding chemotherapy, the success of attempts to supplant R-CHOP-21 for front-line treatment of DLBCL with more dose-dense or dose-intense regimens remains doubtful and this issue is still unresolved. Bendamustine appeared as possibly the most effective cytotoxic agent for treatment of indolent lymphomas, while treatment of HL is becoming more tailored to prognostic features. This decade has also seen the advent of targeted drugs for lymphoma treatment. Their real impact will become known in the years to come. Finally, we may hope that advances in understanding the biology of lymphomas, made in the last decade, will help resolve remaining critical issues, treatment of T-NHLs and high-risk DLBCLs, being probably the most prominent.

Item Type: Article
Departments: Katedra za internu medicinu
Depositing User: Marijan Šember
Status: Published
Date: April 2011
Date Deposited: 13 May 2011
Last Modified: 23 Sep 2011 16:11
Subjects: /
Related URLs:

    Actions (login required)

    View Item View Item


    Downloads per month over past year